Real-World Outcomes of Tisagenlecleucel in Korean DLBCL Patients, 79 Cases

79 patient records from a retrospective study evaluating the efficacy and safety of tisagenlecleucel (CAR T-cell therapy) in Korean patients with relapsed or refractory diffuse large B-cell lymphoma. The data covers patients treated between April 2022 and January 2025 at the Catholic Hematology Hospital, with a median follow-up of 11.6 months. The study was authored by Gi-June Min and published on figshare in April 2026.

Use Cases

• Analyze survival outcomes based on progression-free survival and overall survival metrics
• Model predictors of complete response based on patient characteristics and bridging chemotherapy
• Study adverse event rates and management based on cytokine release syndrome and neurotoxicity incidence

Strengths

• 79 patient records provide a specific cohort size
• Median follow-up of 11.6 months offers a defined observation period
• Data includes specific response rates (ORR 72.9%, CR 64.4%) and survival statistics (median PFS 4.9 months, median OS 21.6 months)

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data may reflect geographic bias inherent to a single-center study in Korea

Provenance

Source

Catholic Hematology Hospital

Collection Method

Retrospective analysis of patient records

Time Range

April 2022 to January 2025

Freshness

Last updated 2026-04-24 04:21:33; freshness should be verified

Geography

Korea